NDASUBCUTANEOUSSOLUTIONPriority Review
Approved
Jun 2025
Lifecycle
Launch
Competitive Pressure
0/100
Data completeness
2/8 — Basic
Priority Review
Drug data last refreshed 4h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
YEZTUGO (lenacapavir sodium) is a subcutaneous small-molecule solution approved by the FDA on June 18, 2025, representing a novel therapeutic approach in its indication class. The drug is administered via subcutaneous injection and is positioned as a first-in-class or best-in-class agent. Specific indication and mechanism of action data are not provided in the current profile.
Growth14.4 years to LOE
As a recent launch (June 2025), YEZTUGO is entering the growth phase with high visibility; commercial teams will be focused on rapid market penetration and establishing formulary position.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on YEZTUGO at launch offers high-visibility career exposure with an opportunity to shape market positioning and establish competitive advantage in an early-stage product lifecycle. The 14-year patent runway provides job security and potential for long-term career development within the brand team or adjacent areas.
Brand ManagerField Sales Representative
Worked on YEZTUGO at Gilead Sciences? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.